MOLECULAR-GENETIC APPROACH TO PREDICTING THE CLINICAL COURSE OF CHRONIC MYELOPROLIFERATIVE NEOPLASMS (CMPNS)
Keywords:
Keywords: chronic myeloproliferative neoplasms (CMPNs), JAK2 V617F, CALR mutation, MPL mutation, ASXL1, risk stratification, next-generation sequencing (NGS) prognosis, overall survival (OS), progression-free survival (PFS)Abstract
Chronic myeloproliferative neoplasms (CMPNs) are clonal hematopoietic disorders characterized by excessive proliferation of myeloid cells. Clinical outcomes vary widely, ranging from indolent disease to progression into myelofibrosis or acute leukemia. Traditional prognostic models based on clinical parameters often lack precision. Molecular-genetic profiling, including driver mutations (JAK2, CALR, MPL) and additional high-risk mutations (ASXL1, SRSF2, EZH2, IDH1/2, TP53), has significantly improved risk stratification. This study evaluates the prognostic value of molecular-genetic profiling in 150 CMPN patients. An integrated prognostic model combining clinical and genetic factors demonstrated superior predictive power for overall survival (OS) and progression-free survival (PFS). The findings support the use of molecular-genetic approaches for personalized patient management and therapeutic decision-making.
References
1. Arber DA, et al. The 2016 revision to the WHO classification of myeloid neoplasms and acute leukemia. Blood. 2016.
2. Tefferi A, et al. Mutation-enhanced prognostic models in myelofibrosis. Blood. 2018.
3. Vannucchi AM, et al. Molecular markers in myeloproliferative neoplasms. Leukemia. 2017.
4. Passamonti F, et al. A clinical-molecular prognostic model for myelofibrosis. Blood. 2018.
5. Barbui T, et al. The 2016 revision of WHO classification of myeloproliferative neoplasms: implications for prognosis. Journal of Hematology. 2017.
